California Proposition 38, set for the November 2026 ballot, would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute and the balance awarded via competitive grants, at least $4.2 billion of which must target cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection at 55% reflects concerns over the measure’s eligibility criteria, which critics note appear structured to channel substantial funds to one specific nonprofit backed by its billionaire co-founder, alongside broader worries about long-term General Fund repayment obligations and fragmented state research priorities. Recent analyses from the Legislative Analyst’s Office and opinion pieces have highlighted these design elements and debt implications, contributing to the current market positioning ahead of the vote.